Prognostic Nomogram for Disease-Specific Survival in Patients with Non-metastatic Ampullary Carcinoma After Surgery

Huang-bao Li, MM, Feng-qing Zhao, MM, and Jun Zhou, MM

Department of Hepatobiliary and Pancreatic Surgery, First Hospital of Jiaxing, First Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People’s Republic of China

ABSTRACT

Objective. The aim of this study was to establish and validate an individualized nomogram for predicting disease-specific survival (DSS) in patients with non-metastatic ampullary carcinoma after surgery.

Methods. The nomogram was prepared using retrospective data from the Surveillance, Epidemiology, and End Results database, and included 2022 patients (training dataset: 1276; validation dataset: 746 patients) with non-metastatic ampullary carcinoma who were surgically treated between 2004 and 2014. Cox multivariate regression was performed to identify independent risk factors. The predictive accuracy was determined using the concordance index (C-index) and calibration curves. Results were validated internally using bootstrap resampling, and externally against the validation dataset.

Results. The median follow-up for the training dataset was 25.5 months (range 1–143), the median survival time was 52 months [95% confidence interval (CI) 41.67–62.33], and the postoperative 1-, 3-, and 5-year DSS rates were 86.7%, 57.3%, and 47.2%, respectively. Univariate and multivariate regression analysis demonstrated that age, grade, tumor size, lymph node ratio, extension range, and histology were independent risk factors for DSS. The C-index of the internal validation dataset for predicting DSS was 0.70 (95% CI 0.68–0.72), which was superior to that of the American Joint Committee on Cancer staging, i.e. 0.64 (95% CI 0.62–0.66; p < 0.001). The 5-year DSS and median DSS time for the low-risk group were significantly greater than those for the high-risk group (p < 0.001).

Conclusion. Our nomogram reliably and accurately predicted DSS in patients with non-metastatic ampullary carcinoma after surgery. This model may help clinicians in their decision making.

Ampullary carcinoma is the second most common periampullary malignancy.1 Because it is located at the end of the biliary tract, biliary obstruction occurs at the early stage of disease progression, showing typical symptoms, such as abdominal pain and jaundice. Therefore, it has a relatively high resection rate and better prognosis compared with other periampullary carcinomas.2 For non-metastatic ampullary carcinoma, surgical treatment, especially standard pancreatoduodenectomy, is the current standard treatment.3 The recently released 8th edition of the American Joint Committee on Cancer (AJCC) staging systems for ampullary carcinoma have introduced several improvements over previously used editions with respect to focus on tumor size and number of regional lymph node metastases.4 However, as a prognostic assessment model, many other factors affecting prognosis, such as tumor differentiation and age, are not considered. Moreover, it predicts outcomes in populations rather than in individuals. Therefore, the establishment of a more applicable prognostic evaluation model is necessary.

A nomogram is a simple, multivariate visualization prediction model that uses disease characteristics to determine individualized prognosis.5–10 Compared with traditional methods, nomograms are better predictors of individualized prognosis. However, to our knowledge, a nomogram model for ampullary carcinoma is currently non-existent. This study aimed to develop and validate a nomogram for individualized survival assessments in patients with ampullary carcinoma who were surgically treated.
MATERIALS AND METHODS

Patient Datasets and Study Design

Data of 222 patients with ampullary carcinoma who were surgically treated between 2004 and 2014 were extracted from the Surveillance, Epidemiology, and End Results (SEER) 18 Registries database. We randomly selected patients from six states (Atlanta, Detroit, Greater Georgia, Los Angeles, San Jose, and Seattle; n = 746) to comprise the validation dataset, and the remaining patients (n = 1276) were included in the training dataset.

All patients were diagnosed with ampullary carcinoma on the basis of histopathological examination. The analyzed variables included sex, age at diagnosis, race, marital status at diagnosis, grade, histology, regional nodes examined (RNE), regional nodes positive (RNP), lymph node ratio (LNR, defined as the number of RNP divided by the RNE), tumor size, extension range, AJCC stage, cause-specific death classification, and survival in months. Follow-up ended in December 2015, and the primary endpoint was disease-specific survival (DSS), which was calculated as the interval between the date of diagnosis and the date of death from ampullary carcinoma.

The inclusion and exclusion criteria were consistent between the training and validation groups and are detailed as follows.

Inclusion criteria (a) Primary site of the tumor: (CS Schema v0204+, ampulla vater); (b) year of diagnosis: 2004–2015; and (c) no history of another malignant tumor (sequence number: one primary only; first malignant primary indicator: yes).

Exclusion criteria: (a) Non-operative treatment [RX Summ–Surg Prim Site (1998+): 0–27]; (b) age < 18 years; (c) tumor size unreported; (d) grade unreported; (e) survival time mismatch with the year of diagnosis; and (f) other variables that are unknown or are missing from the database.

Histologically, ampullary carcinoma is routinely divided into the pancreaticobiliary and intestinal subtypes, but the classification used in this study is based on the International Classification of Diseases for Oncology, Third Revision (ICD-O-3). Histological subtypes defined as ‘others’ were adenocarcinoma of the intestinal type (8144), adenocarcinoma in an adenomatous polyp (8210), adenocarcinoma with a mixed subtype (8255), papillary adenocarcinoma (8260), adenocarcinoma in a villous adenoma (8261), villous adenocarcinoma (8262), mucinous adenocarcinoma (8480), and signet ring cell carcinoma (8490). Extension range defined as ‘localized’ were tumors limited to the ampulla of Vater or extending to the sphincter of Oddi. Extension range defined as ‘adjacent organs or tissues’ were the tumor invades the following organs or tissues: blood vessel(s) [major]—hepatic artery, portal vein; gallbladder; hepatic flexure of the colon; lesser omentum; liver, including the porta hepatis; stomach; transverse colon; and peripancreatic soft tissue.

Statistical Analysis

Summary statistics for the study population are presented as percentages or median values. The Mann–Whitney U test was used for continuous variables with a non-parametric distribution of patient data at baseline. The continuous variables were transformed into categorical variables to match the nomogram. The best cut-off points of continuous variables were identified using X-tile software (Rimm Laboratory, Yale School of Medicine, New Haven, CT, USA) for outcome-based optimization. Categorical variables were grouped according to clinical findings, and associations among categorical variables were tested using the Chi square test. Independent risk factors were screened by univariate analysis (log-rank) and forward stepwise Cox multivariate regression analysis using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). The DSS rate and median DSS were calculated using a life (actuarial) table method.

The nomogram was developed on the basis of independent risk factors and using the rms package in R version 3.5.0 (The R Project for Statistical Computing, Vienna, Austria). The predictive capacity of the nomogram was assessed using Harrell’s C-index (the concordance statistic, or C-statistic), which estimates the probability between the observed and predicted DSS. A random resampling procedure (bootstrapping) with 1000 resamples was used for internal validation, and the nomogram was externally validated with the validation dataset. The DSS derived from the developed nomogram, and the AJCC staging system, were compared using the rcorr.p.cens (Hmisc) package in R and were assessed using the C-index.

The scores of each variable were calculated using the nomogramEx package in R. On the basis of the scores of each variable, the total DSS scores for each patient could be calculated. On the basis of the nomogram score, patients were then divided into low A-, low B-, moderate-, and high-risk groups. The 1-, 3-, and 5-year DSS rates and the median DSS time of each group were calculated, and the Kaplan–Meier survival curves were plotted. A p value < 0.05 was considered statistically significant.

RESULTS

Patient Clinicopathologic Characteristics

In the training dataset, the ratio of men to women was 1.32:1 (725/551). The median patient age was 66 years, and adenocarcinoma accounted for 77.7% of the carcinomas. Most patients had early-stage AJCC tumors (I + II,
and better differentiation (well + moderately differentiated, 66.1%). Table 1 presents all other patient clinicopathologic characteristics.

**Disease-Specific Survival (DSS) and Independent Risk Factors in the Training Dataset**

The median follow-up was 25.5 months (range 1–143). The median survival time was 52 months [95% confidence interval (CI) 41.67–62.33], and the postoperative 1-, 3-, and 5-year DSS rates were 86.7%, 57.3%, and 47.2%, respectively. Univariate analysis demonstrated that age, grade, tumor size, RNP, LNR, extension range, and histology were risk factors for DSS, while multivariate analysis demonstrated that age, grade, tumor size, LNR, extension range, and histology were independent risk factors for DSS (Table 2). Sex, race, marital status, and RNE were not statistically significant in determining prognosis.

**Prognostic Nomogram for DSS**

Figure 1 shows the nomogram, which was generated using a Cox proportional hazards model that included all significant independent prognostic factors for DSS in the

### Table 1: Demographic and clinicopathologic characteristics of non-metastatic ampullary carcinoma patients after surgery

| Demographic or characteristic | Training dataset | Validation dataset | p value |
|------------------------------|------------------|--------------------|---------|
| Sex                          |                  |                    |         |
| Male                         | 725              | 425                | 0.947   |
| Female                       | 551              | 321                |         |
| Age, years [median (IQR)]    | 66 (57–74)       | 64 (56–72)         | 0.021   |
| Race                         |                  |                    |         |
| White                        | 1017             | 534                | < 0.001 |
| Black                        | 65               | 86                 | 0.177   |
| Others                       | 194              | 126                | 0.407   |
| Marital status               |                  |                    |         |
| Yes                          | 825              | 460                | 0.053   |
| No                           | 451              | 286                |         |
| Grade                        |                  |                    |         |
| Well-differentiated          | 134              | 86                 | 0.407   |
| Moderately differentiated    | 710              | 386                |         |
| Poorly differentiated        | 423              | 268                |         |
| Undifferentiated             | 9                | 6                  |         |
| Histology                    |                  |                    |         |
| Adenocarcinoma               | 991              | 583                | 0.229   |
| Others                       | 285              | 143                |         |
| Regional nodes examined [median (IQR)] | 13 (8–19) | 14 (9–12) | 0.017 |
| Regional nodes positive [median (IQR)] | 1 (0–2) | 1 (0–3) | 0.003 |
| LNR [median (IQR)]           | 0.05 (0.00–0.20) | 0.07 (0.00–0.22) | 0.010 |
| Tumor size, mm [median (IQR)]| 21 (15–30)       | 22 (15–32)         | 0.336   |
| Extension range              |                  |                    |         |
| Localized                    | 156              | 92                 | 0.682   |
| Duodenal wall                | 364              | 203                |         |
| P/C/E                        | 490              | 284                |         |
| Adjacent organs or tissues   | 266              | 167                |         |
| AJCC stage                   |                  |                    |         |
| IA                           | 123              | 67                 | 0.468   |
| IB                           | 219              | 114                |         |
| IIA                          | 169              | 88                 |         |
| IIB                          | 417              | 268                |         |
| III                          | 348              | 209                |         |

P/C/E = pancreas, common bile duct, extrahepatic bile duct, LNR = lymph node ratio, AJCC = American Joint Committee on Cancer, IQR = interquartile range
training dataset. The C-index of the internal validation for DSS prediction was 0.70 (95% CI 0.68–0.72), and the calibration curves for the probability of postoperative DSS at 5 years (Fig. 2a) suggested good consistency between the observed and predicted values. The nomogram showed superior performance compared with the AJCC staging system (C-index = 0.64, 95% CI 0.62–0.66; p < 0.001).

Table 2 shows the scores of each variable. Patients with probability total scores < 120, 120–180, 180–240, and ≥ 240 were assigned to the low A-, low B-, moderate-, and high-risk groups, respectively. According to the prognosis curve predicted by different stages, discrimination of nomogram-predicted stages was better than that of AJCC stages. The 5-year DSS rates of the low A-, low B-, moderate-, and high-risk groups were 78.8%, 61.3%, 33.8%, and 20.1%, respectively. In addition, the median DSS time were 32 and 21 months for the moderate- and high-risk groups, respectively. The low-risk group had a 5-year survival rate of more than 50%, and had no median survival time. The 5-year DSS rates and median DSS time of patients were significantly higher in the low-risk group than in the high-risk group (p < 0.001).

**Validation of Predictive Accuracy of the Nomogram**

In the validation dataset, the median DSS time was 43 months (95% CI 36.25–49.75), and the 1-, 3-, and 5-year DSS rates were 85.6%, 55.3%, and 42.2%, respectively. The C-index of the nomogram for DSS prediction was 0.70 (95% CI 0.67–0.73), and the calibration curve

### TABLE 2 Univariate and multivariate analysis of the training dataset and variable score

| Variable                  | Score | Univariate analysis | Multivariate analysis |
|---------------------------|-------|---------------------|-----------------------|
|                           |       | 5-year survival (%) | p value               | HR   | 95% CI       | p value |
| Age, years                |       |                     | < 0.001               | < 0.001 | < 0.001 |
| < 56                      | 0     | 55.0                |                       | 1     |              |        |
| 56–73                     | 32.07 | 48.8                | 1.24                  | 0.98–1.57 | 0.071 |
| > 73                      | 64.14 | 37.4                | 1.89                  | 1.46–2.44 | < 0.001 |
| Grade                     |       |                     | < 0.001               | < 0.001 | < 0.001 |
| Well differentiated       | 0     | 67.7                |                       | 1     |              |        |
| Moderately differentiated | 23.05 | 49.7                | 1.30                  | 0.93–1.81 | 0.124 |
| Poorly differentiated     | 46.10 | 35.4                | 1.72                  | 1.22–2.42 | 0.002 |
| Undifferentiated          | 69.15 | –                   | 0.22                  | 0.03–1.60 | 0.134 |
| Tumor size (mm)           |       |                     | < 0.001               | 0.030  |       |
| ≤ 14                      | 0     | 62.7                |                       | 1     |              |        |
| > 14                      | 27.63 | 43.0                | 1.31                  | 1.03–1.68 |        |
| RNP                       |       |                     | < 0.001               | < 0.001 | < 0.001 |
| 0                         | –     | 64.8                |                       | 1     |              |        |
| 1–2                       | –     | 34.6                |                       |       |              |        |
| 3–7                       | –     | 24.8                |                       |       |              |        |
| > 7                       | –     | 22.5                |                       |       |              |        |
| LNR                       |       |                     | < 0.001               | < 0.001 | < 0.001 |
| 0                         | 0     | 64.8                |                       | 1     |              |        |
| ≤ 0.21                    | 50    | 34.6                | 1.87                  | 1.50–2.32 | < 0.001 |
| > 0.21                    | 100   | 24.1                | 2.70                  | 2.16–3.39 | < 0.001 |
| Histology                 |       |                     | < 0.001               | 0.006  |       |
| Adenocarcinoma            | 29.98 | 44.4                |                       | 1     |              |        |
| Others                    | 0     | 56.7                | 0.74                  | 0.59–0.92 |       |
| Extension range           |       |                     | < 0.001               | < 0.001 | < 0.001 |
| Localized                 | 0     | 67.9                |                       | 1     |              |        |
| Duodenal wall             | 25.39 | 62.7                | 1.02                  | 0.70–1.48 | 0.912 |
| P/C/E                     | 50.78 | 37.4                | 1.78                  | 1.25–2.54 | 0.001 |
| Adjacent O/T              | 76.18 | 31.6                | 1.82                  | 1.24–2.67 | 0.002 |

*HR* hazard ratio, *CI* confidence interval, *RNP* regional nodes positive, *LNR* lymph node ratio, *P/C/E* pancreas, common bile duct, extrahepatic bile duct, *Adjacent O/T* adjacent organs or tissues
DISCUSSION

Accurate prognostication is essential to select perioperative therapy. However, to our knowledge, with the exception of the AJCC guidelines, there is no prognostic model for ampullary cancer, although a few studies have reported nomograms for periampullary carcinoma, including three different types, namely ampullary carcinoma, distal bile duct cancer, and pancreatic cancer, each with unique disease characteristics. They are all treated with pancreatoduodenectomy and have different prognoses. Therefore, these nomograms are unsuitable for ampullary carcinoma.

The present nomogram was constructed and validated using multivariate analysis, with age, grade, tumor size, LNR, extension range, and histology as independent risk factors. Although the 8th edition of the AJCC guidelines redefines the grouping of RNP and confirms its impact on prognosis, our study showed that LNR greatly impacts the nomogram, whereas the effect of the number of RNP is excluded from the Cox multivariate analysis. The result indicates that LNR plays an important role in prognosis assessment of ampullary carcinoma, a fact that has been demonstrated in other studies. LNR is incorporated into two variables—RNP and RNE; it not only considers the impact of RNP but also the impact of the total number of RNE on prognosis. Previous studies have shown that insufficient lymphatic dissection (RNEs) may result in the loss of positive lymph nodes (RNP) that have been

suggested good consistency between the observed and predicted 5-year DSS (Fig. 2b).
metastasized, which might lead to residual metastases. Tumor grade is also an important factor affecting prognosis. In this study, we found that 66.1% of ampullary carcinomas (Table 2), but the prognosis is worse in comparison with that of other types. It is important to note that signet ring cell carcinoma often has a very poor prognosis, and although it is included in the ‘other’ group in this study, we do not recommend the use of this nomogram to assess the prognosis of the type.

The nomogram has the following advantages. First, the nomogram was superior to the current AJCC staging system in predicting DSS. This is not only reflected in its higher C-index value but also in the effect of differentiating the prognoses in different stages, as shown in Fig. 3. This is most likely because of the AJCC system only taking into account the tumor size, positive regional lymph nodes, and metastasis. However, age, LNR, differentiation grade, and extension of invasion were also independent risk factors for prognosis. Second, in practical terms, the variables used in the nomogram are easily obtained from patients with ampullary carcinoma who are treated surgically. By using the variable score, clinicians can immediately and accurately predict the prognosis and gain useful information regarding postoperative treatments. Third, clinical and pathological information of the nomogram is derived from the SEER database registered in 18 states of the US, which has features of multicenter clinical data; therefore, the results should be more applicable to the general population than if they were developed at a single institution.

When using this nomogram, we should pay attention to the following points. First, data were collected retrospectively. Second, the use of open access data from the SEER database did not include data on chemotherapy or the major comorbidities prevalent that could affect prognosis. Therefore, in the future, the prognostic disease-specific nomogram developed in this study should undergo external validation using an independent dataset.

CONCLUSIONS

A prognostic disease-specific nomogram for patient survival in ampullary carcinoma after surgery was developed and validated. Clinicopathologic variables, including patient age, grade, tumor size, LNR, extension range, and histology were independent risk factors for postoperative prognosis. According to the score of the nomogram, because of the higher long-term survival rate, whether patients in the low-risk A group need excessive chemotherapy or radiotherapy needs further clinical observation. Moreover, patients in the high-risk group may have a poor prognosis and may need more active postoperative treatment and should be followed up more closely. Although this was a preliminary study, the nomogram was predictive of DSS in ampullary carcinoma patients who underwent surgery, and this model should be further evaluated in future clinical studies.

ACKNOWLEDGMENT The authors thank the SEER program database for providing open data.

FUNDING The work was supported by the Science and Technology Project of Jiaxing (Grant No. 2018AY32015).
REFERENCES

1. O’Connell JB, Maggard MA, Manunga J Jr, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008;15(7):1820–1827.
2. Gonzalez RS, Bagci P, Basturk O, et al. Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. Mod Pathol. 2016;29(11):1358–1369.
3. Chandrasegaram MD, Gill AJ, Samra J, et al. Ampullary cancer of intestinal origin and duodenal cancer—a logical clinical and therapeutic subgroup in periampullary cancer. World J Gastrointest Oncol. 2017;9(10):407–415.
4. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. Chicago, IL: Springer; 2017.
5. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370.
6. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180.
7. Young KA, Efiong E, Dove JT, et al. External validation of a survival nomogram for non-small cell lung cancer using the national cancer database. Ann Surg Oncol. 2017;24(6):1459–1464.
8. Demey K, Wolthuis A, de Buck van Overstraeten A, et al. External validation of the prognostic nomogram (COMPASS) for patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2017;24(12):3604–3608.
9. Zheng ZF, Lu J, Wang W, et al. Development and external validation of a simplified nomogram predicting individual survival after R0 resection for gastric cancer: an international, multicenter study. Ann Surg Oncol. 2018;25(8):2383–2390.
10. Li HB, Zhou J, Zhao FQ. A prognostic nomogram for diseasespecific survival in patients with pancreatic ductal adenocarcinoma of the head of the pancreas following pancreatoduodenectomy. Med Sci Monit. 2018;24:6313–6321.
11. Doepker MP, Thompson ZJ, Centeno BA, Kim RD, Wong J, Hodul PJ. Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. J Surg Oncol. 2016;114(2):170–175.
12. Reid MD, Balci S, Ohike N, et al. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreaticobiliary versus intestinal in 232 cases. Mod Pathol. 2016;29(12):1575–1585.
13. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
14. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–2546.
15. He C, Mao Y, Wang J, Duan F, Lin X, Li S. Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy. BMC Cancer. 2018;18(1):327.
16. Tol JA, Brosens LA, van Dieren S, et al. Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer. Br J Surg. 2015;102(3):237–245.
17. Kwon J, Kim K, Chie EK, et al. Prognostic relevance of lymph node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant treatment. Eur J Surg Oncol. 2017;43(9):1690–1696.
18. Chen SC, Shyr YM, Chou SC, Wang SE. The role of lymph nodes in predicting the prognosis of ampullary carcinoma after curative resection. World J Surg Oncol. 2015;13:224.
19. Partelli S, Crippa S, Capelli P, et al. Adequacy of lymph node retrieval for ampullary cancer and its association with improved staging and survival. World J Surg. 2013;37(6):1397–1404.
20. Okano K, Oshima M, Yachida S, et al. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma. J Surg Oncol. 2014;110(2):156–162.
21. Wen X, Wu W, Wang B, Yao H, Teng X. Signet ring cell carcinoma of the ampulla of Vater: Immunophenotype and differentiation. Oncol Lett. 2014;8(4):1687–1692.
22. Jin Z, Hartgers ML, Sahinueza CT, et al. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol. 2018;44(5):677–683.
23. Stiles ZE, Behrman SW, Den eve JL, et al. Ampullary adenocarcinoma: defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease. J Surg Oncol. 2018;117(7):1500–1508.